US FDA approves IASO Bio clinical trial application for BCMA CAR-T CT103A for relapsed/refractory multiple myeloma
IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company, announced that the Investigational New Drug (IND) application for its in-house developed BCMA CAR-T CT103A (equecabtagene autoleucel) has been approved by the US Food and Drug Administration (FDA) for use in US clinical trials for relapsed/refractory multiple myeloma (R/R MM).
Multiple myeloma is a deadly blood cancer that often infiltrates the bone marrow causing anaemia, kidney failure, immune problems, and bone fractures. For multiple myeloma patients, common first-line drug treatments include proteasome inhibitors, immunomodulatory drugs, and alkylating agents. While treatment may result in remission, most patients will inevitably enter the relapsed or refractory stage as there
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!